Company Overview
Align Technology, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by providing orthodontic solutions such as Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services to patients in the United States, Switzerland, and international markets. The company's core business model centers on delivering comprehensive packages to treat malocclusion in both adult and teenage populations, leveraging proprietary manufacturing and digital scanning technologies. This enterprise holds a substantial market capitalization of $12.65B and generated annual revenue of $4.03B over the trailing twelve months, supported by a workforce of 20,290 employees. These valuation and revenue figures indicate that Align Technology is a significant player in the specialized medical device space, commanding a large market presence that reflects its established brand recognition and global operational footprint. The combination of a high market cap and robust revenue stream suggests the company has achieved a level of scale that allows for extensive R&D investment and global distribution network expansion.
Financial Health
The company reported revenue of $4.03B and net income of $410.35M for the trailing twelve months, resulting in an EBITDA of $851.35M, which highlights a substantial operational efficiency before interest, taxes, depreciation, and amortization. The gap between the $4.03B revenue and $410.35M net income reveals a profit margin of 10.2%, indicating that the company maintains a healthy bottom line while managing significant cost structures inherent to manufacturing and distribution. Free cash flow stands at $483.69M, providing the company with considerable financial flexibility to fund capital expenditures, invest in technology upgrades, or pursue strategic acquisitions without needing to raise external capital. The gross margin is recorded at 69.8%, demonstrating the high value of the proprietary aligner products relative to their cost of goods sold. The operating margin sits at 22.4%, reflecting the company's ability to control overhead expenses effectively, while the profit margin of 10.2% confirms the final earnings available to shareholders after all expenses. Liquidity is supported by cash reserves of $1.09B against total debt of $114.45M, resulting in a debt-to-equity ratio of 2.83, which indicates a balance sheet that carries leverage but maintains sufficient asset backing. The current ratio of 1.36 suggests the company possesses adequate short-term assets to cover its short-term liabilities, ensuring stability in its liquidity position. Return on equity is 10.4% and return on assets is 6.9%, metrics that reveal management's effectiveness in generating profits from shareholders' investments and utilizing the company's asset base efficiently.
Valuation Assessment
The trailing twelve-month P/E ratio is 31.14, while the forward P/E is projected at 14.34, a significant disparity that implies the market expects a substantial increase in earnings growth to justify the current high valuation multiple. The price-to-book ratio stands at 3.11, indicating that the market values the company at more than three times its book value, which suggests a premium assigned to its intangible assets, brand equity, and proprietary technology. Alternative valuation metrics further contextualize the company's pricing, with a price-to-sales ratio of 3.13 and an EV/EBITDA of 13.61, suggesting that investors are willing to pay a premium for revenue and earnings quality relative to peers. The stock price has fluctuated within a range defined by a 52-week high of $208.31 and a 52-week low of $122.00, providing a historical context for current price movements and volatility. The beta value of 1.82 indicates that the stock price is significantly more volatile than the broader market, moving with approximately 1.8 times the magnitude of general market swings. This high beta characteristic means that the stock will experience amplified price swings during periods of market stress or rally, reflecting the higher risk profile associated with the company's specific sector dynamics.
Growth & Income
Revenue growth year-over-year is 5.3%, while earnings growth year-over-year is 35.6%, demonstrating that earnings are expanding at a rate far faster than revenue, which often implies improving operational leverage or margin expansion. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders but instead retains earnings to fuel internal growth initiatives, R&D, and business expansion. This reinvestment strategy aligns with the growth profile of a medical technology firm that prioritizes capital allocation toward innovation and market share acquisition rather than passive income generation. The overall growth and income profile is characterized by strong earnings acceleration that outpaces top-line revenue growth, supported by a zero-dividend policy that directs all financial returns toward compounding the business value.